MMMitsuru Miyachi

Mitsuru Miyachi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mitsuru Miyachi has a total of 169 co-authors. Here are the top co-authors by number of shared publications:

  • Kunihiko Tsuchiya

    Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

    15 shared publications
  • Ken Kikuchi

    Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602‑8566, Japan

    13 shared publications
  • Hajime Hosoi

    Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

    11 shared publications
  • Tomoko Iehara

    Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

    11 shared publications
  • Tomoko Iehara

    Department of Pediatrics, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan

    11 shared publications
  • Eiichi Konishi

    Department of Surgical Pathology, Kyoto Prefectural University of Medicine, Kyoto, Japan

    10 shared publications

Latest Publications

  • Open Access

    Pain Assessment Tools for Infants, Children, and Adolescents With Cancer: A Scoping Review

    by Noyuri Yamaji, Mika Hirata, Yuko Nagoya, Wataru Irie, Shotaro Iwamoto, Mitsuru Miyachi, Takashi Yamaguchi, Daisuke Hasegawa, Erika Ota, Nobuyuki Yotani

    Background: Pain assessment is essential for effectively managing pain in pediatric oncology. Despite various tools being used globally, few comprehensive studies summarize their features; this complicates the selection of appropriate tools. This scoping review aimed to map the existing literature on pain assessment tools for children with cancer. Methods: On November 20, 2023, we followed the guidelines of the Joanna Briggs Institute Manual for Evidence Synthesis and conducted a comprehensive search of PubMed, Cumulative Index to Nursing and Allied Health Literature, Cochrane Central Register of Controlled Trials, Embase, and Ichushi‐Web. Studies describing pain assessment tools for children aged 0–18 years were included. The tools were categorized as self‐reporting and proxy reporting. As this study aimed to map, a critical appraisal of study quality was not performed. Results: We identified 33 pain assessment tools across 48 studies: 18 self‐report measures, 10 proxy‐rated measures, and five hybrid tools. Commonly identified tools included the visual analog scale (VAS), Numeric Rating Scale (NRS), Wong–Baker FACES Pain Rating Scale, and Face, Legs, Activity, Cry, Consolability (FLACC) Scale. Formats varied from visual scales to digital applications. Several tools used illustrations, making them accessible to children as young as 3–4 years. Most tools were originally developed in English for non‐cancer populations, with few validated translations or cultural adaptations. Conclusion: This review maps available tools for assessing pediatric cancer pain and highlights the need for age‐appropriate multidimensional approaches that prioritize self‐reporting. Further research should focus on validation and cultural adaptation across diverse groups of children with cancer.


  • Open Access

    Figure S1 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors

    by Satoru Oya, Hideki Yoshida, Akimasa Tomida, Mitsuru Miyachi, Shigeki Yagyu, Yoshiki Katsumi, Ken Kikuchi, Kunihiko Tsuchiya, Eiichi Konishi, Subbaya Subramanian, et al.

    Figure S1 shows Map of the SALL4 promoter (pSALL4) region in human and structure of pSALL4-OAd.

  • Open Access

    Table S1 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors

    by Satoru Oya, Hideki Yoshida, Akimasa Tomida, Mitsuru Miyachi, Shigeki Yagyu, Yoshiki Katsumi, Ken Kikuchi, Kunihiko Tsuchiya, Eiichi Konishi, Subbaya Subramanian, et al.

    Table S1 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors

  • Open Access

    Figure S4 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors

    by Satoru Oya, Hideki Yoshida, Akimasa Tomida, Mitsuru Miyachi, Shigeki Yagyu, Yoshiki Katsumi, Ken Kikuchi, Kunihiko Tsuchiya, Eiichi Konishi, Subbaya Subramanian, et al.

    Figure S4 shows Isotype control staining

  • Open Access

    Figure S2 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors

    by Satoru Oya, Hideki Yoshida, Akimasa Tomida, Mitsuru Miyachi, Shigeki Yagyu, Yoshiki Katsumi, Ken Kikuchi, Kunihiko Tsuchiya, Eiichi Konishi, Subbaya Subramanian, et al.

    SALL4 expression in Rhabdoid Tumors in the TARGET database

  • Open Access

    Figure S3 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors

    by Satoru Oya, Hideki Yoshida, Akimasa Tomida, Mitsuru Miyachi, Shigeki Yagyu, Yoshiki Katsumi, Ken Kikuchi, Kunihiko Tsuchiya, Eiichi Konishi, Subbaya Subramanian, et al.

    Figure S3 shows expression of CLDN6 and USP44 mRNA in RT cell lines

  • Open Access

    Data from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors

    by Satoru Oya, Hideki Yoshida, Akimasa Tomida, Mitsuru Miyachi, Shigeki Yagyu, Yoshiki Katsumi, Ken Kikuchi, Kunihiko Tsuchiya, Eiichi Konishi, Subbaya Subramanian, et al.

    Rhabdoid tumors (RT) are highly aggressive pediatric malignancies with limited treatment options. SALL4, a gene essential for embryonic stem cell pluripotency and self-renewal, is frequently overexpressed in RTs. To exploit this, we developed a conditionally replicating oncolytic adenovirus (pSALL4-OAd) by placing the E1 region under the control of the SALL4 promoter, restricting viral replication to SALL4-positive cells. SALL4 protein expression was analyzed in 10 clinical RT specimens via IHC, whereas SALL4 mRNA levels and promoter activity were assessed in eight RT cell lines using qPCR and dual-luciferase assays. The replication selectivity and cytopathic effects of pSALL4-OAd were tested in vitro at doses of 0 to 1,000 viral particles/cell. In vivo, 1.0 × 107 G401 cells were implanted subcutaneously into immunodeficient mice, followed by intratumoral administration of pSALL4-OAd (3 × 1010 viral particles) or PBS. Tumor growth was monitored over the treatment period. SALL4 protein was detected in 40% of clinical RT specimens, and RT cell lines exhibited four- to 400-fold higher SALL4 mRNA levels compared with normal tissues. Elevated SALL4 promoter activity was confirmed in three of five RT cell lines. pSALL4-OAd selectively replicated in SALL4-positive cells and induced significant cytopathic effects proportional to promoter activity in vitro. In vivo, pSALL4-OAd administration caused tumor necrosis, reduced SALL4-positive cells, and suppressed tumor proliferation. These results demonstrate the potential of pSALL4-OAd as a targeted and effective therapeutic strategy for SALL4-expressing RTs.

  • A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors

    by Satoru Oya, Hideki Yoshida, Akimasa Tomida, Mitsuru Miyachi, Shigeki Yagyu, Yoshiki Katsumi, Ken Kikuchi, Kunihiko Tsuchiya, Eiichi Konishi, Subbaya Subramanian, et al.

    Rhabdoid tumors (RT) are highly aggressive pediatric malignancies with limited treatment options. SALL4, a gene essential for embryonic stem cell pluripotency and self-renewal, is frequently overexpressed in RTs. To exploit this, we developed a conditionally replicating oncolytic adenovirus (pSALL4-OAd) by placing the E1 region under the control of the SALL4 promoter, restricting viral replication to SALL4-positive cells. SALL4 protein expression was analyzed in 10 clinical RT specimens via IHC, whereas SALL4 mRNA levels and promoter activity were assessed in eight RT cell lines using qPCR and dual-luciferase assays. The replication selectivity and cytopathic effects of pSALL4-OAd were tested in vitro at doses of 0 to 1,000 viral particles/cell. In vivo, 1.0 × 107 G401 cells were implanted subcutaneously into immunodeficient mice, followed by intratumoral administration of pSALL4-OAd (3 × 1010 viral particles) or PBS. Tumor growth was monitored over the treatment period. SALL4 protein was detected in 40% of clinical RT specimens, and RT cell lines exhibited four- to 400-fold higher SALL4 mRNA levels compared with normal tissues. Elevated SALL4 promoter activity was confirmed in three of five RT cell lines. pSALL4-OAd selectively replicated in SALL4-positive cells and induced significant cytopathic effects proportional to promoter activity in vitro. In vivo, pSALL4-OAd administration caused tumor necrosis, reduced SALL4-positive cells, and suppressed tumor proliferation. These results demonstrate the potential of pSALL4-OAd as a targeted and effective therapeutic strategy for SALL4-expressing RTs.


  • Open Access

    Pain Assessment Tools for Infants, Children, and Adolescents With Cancer: Protocol for a Scoping Review

    by Mika Hirata, Noyuri Yamaji, Shotaro Iwamoto, Ayaka Hasegawa, Mitsuru Miyachi, Takashi Yamaguchi, Daisuke Hasegawa, Erika Ota, Nobuyuki Yotani, Japanese Society for Palliative Medicine

    Background: Pain management in children with cancer may be inadequate due to poor pain assessment, and evaluation using suitable tools is necessary. Despite the availability of many pain assessment scales, few studies have summarized the existing assessment tools, making it challenging to select a suitable scale. Objective: This scoping review aims to map existing pain assessment tools for children with cancer and provide a comprehensive overview of pediatric cancer-related pain screening and assessment tools. Methods: The scoping review will be conducted according to the guidelines by the Joanna Briggs Institute and reported following the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) framework. Electronic databases, including PubMed, CINAHL, CENTRAL, ICHUSHI (Japan Medical Abstracts Society), and Embase, will be searched to identify eligible studies, without date or language restrictions. We defined the eligibility criteria based on the PCC (Population, Concept, and Context) format. Studies that focused on assessment tools for evaluating pain in children (aged 0-18 years) with cancer in a hospital or at home will be included. Although there are no restrictions on study design, protocols and conference abstracts will be excluded. Two or more reviewers will select studies by reviewing the full text of relevant articles identified by titles and abstracts, and disagreements will be resolved through discussion. Two or more reviewers will extract predefined data items, including characteristics of included studies (eg, author name, title of publication, year of publication, purpose of study, study setting, study population, outline of the assessment tool, study design, and findings) and the characteristics of assessment tools (eg, types of tools, target population, assessor, validity, instructions, precautions, and advantages and disadvantages of the tools). Pain assessment tools will be summarized in tabular format and described in a narrative synthesis. Results: Through electronic database searches on November 20, 2023, we identified 3748 articles. This review will provide a comprehensive overview of pain assessment tools. The final report is planned for submission to a peer-reviewed journal in 2025. Conclusions: This scoping review is the first comprehensive effort to map existing tools on pediatric cancer-related pain assessment tools for infants, children, and adolescents aged <18 years, according to developmental stages. Based on the findings of this study, we will discuss future clinical and research implications for pain assessment and management in children with cancer. The findings are expected to enhance pain management practices in children with cancer and inform health care providers, policy makers, and other stakeholders. International Registered Report Identifier (IRRID): DERR1-10.2196/66614


  • Open Access

    Pain Assessment Tools for Infants, Children, and Adolescents With Cancer: Protocol for a Scoping Review (Preprint)

    by Mika Hirata, Noyuri Yamaji, Shotaro Iwamoto, Ayaka Hasegawa, Mitsuru Miyachi, Takashi Yamaguchi, Daisuke Hasegawa, Erika Ota, Nobuyuki Yotani

    BACKGROUND Pain management in children with cancer may be inadequate due to poor pain assessment, and evaluation using suitable tools is necessary. Despite the availability of many pain assessment scales, few studies have summarized the existing assessment tools, making it challenging to select a suitable scale. OBJECTIVE This scoping review aims to map existing pain assessment tools for children with cancer and provide a comprehensive overview of pediatric cancer-related pain screening and assessment tools. METHODS The scoping review will be conducted according to the guidelines by the Joanna Briggs Institute and reported following the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) framework. Electronic databases, including PubMed, CINAHL, CENTRAL, ICHUSHI (Japan Medical Abstracts Society), and Embase, will be searched to identify eligible studies, without date or language restrictions. We defined the eligibility criteria based on the PCC (Population, Concept, and Context) format. Studies that focused on assessment tools for evaluating pain in children (aged 0-18 years) with cancer in a hospital or at home will be included. Although there are no restrictions on study design, protocols and conference abstracts will be excluded. Two or more reviewers will select studies by reviewing the full text of relevant articles identified by titles and abstracts, and disagreements will be resolved through discussion. Two or more reviewers will extract predefined data items, including characteristics of included studies (eg, author name, title of publication, year of publication, purpose of study, study setting, study population, outline of the assessment tool, study design, and findings) and the characteristics of assessment tools (eg, types of tools, target population, assessor, validity, instructions, precautions, and advantages and disadvantages of the tools). Pain assessment tools will be summarized in tabular format and described in a narrative synthesis. RESULTS Through electronic database searches on November 20, 2023, we identified 3748 articles. This review will provide a comprehensive overview of pain assessment tools. The final report is planned for submission to a peer-reviewed journal in 2025. CONCLUSIONS This scoping review is the first comprehensive effort to map existing tools on pediatric cancer-related pain assessment tools for infants, children, and adolescents aged <18 years, according to developmental stages. Based on the findings of this study, we will discuss future clinical and research implications for pain assessment and management in children with cancer. The findings are expected to enhance pain management practices in children with cancer and inform health care providers, policy makers, and other stakeholders. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/66614